Related references
Note: Only part of the references are listed.Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair-Deficient Cancers
Sarah A. Martin et al.
CANCER RESEARCH (2011)
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Ignacio Varela et al.
NATURE (2011)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Rad52 inactivation is synthetically lethal with BRCA2 deficiency
Zhihui Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
Sarah A. Martin et al.
CANCER CELL (2010)
Poly(ADP-Ribose) Polymerase Inhibitor Induces Accelerated Senescence in Irradiated Breast Cancer Cells and Tumors
Elena V. Efimova et al.
CANCER RESEARCH (2010)
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
Ponnari Gottipati et al.
CANCER RESEARCH (2010)
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Brian McEllin et al.
CANCER RESEARCH (2010)
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Norman Chan et al.
CANCER RESEARCH (2010)
Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
Oren Gilad et al.
CANCER RESEARCH (2010)
Slaying RAS with a synthetic lethal weapon
Archana Bommi-Reddy et al.
CELL RESEARCH (2010)
Targeting cancer cells through autophagy for anticancer therapy
Sandra Turcotte et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
PARP inhibition in BRCA-mutated breast and ovarian cancers
Stephen L. Chan et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
Dana A. Loeser et al.
MOLECULAR CANCER THERAPEUTICS (2010)
PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations
Lisa Hutchinson
Nature Reviews Clinical Oncology (2010)
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
Dun Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Role of Tyrosine Kinase Inhibitors in Lung Cancer
J. Ansari et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Recent advances in p53 research: an interdisciplinary perspective
M. Olivier et al.
CANCER GENE THERAPY (2009)
Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers
Charles L. Sawyers
CELL (2009)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Claudia Scholl et al.
CELL (2009)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Alison C. Young et al.
CLINICAL CANCER RESEARCH (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
Henning Willers et al.
MOLECULAR CANCER RESEARCH (2009)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
NF-κB: A Key Player in Lung Cancer
[Anonymous]
CELL (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect
Yijun Chen et al.
PLOS ONE (2009)
Synthetic lethality: a framework for the development of wiser cancer therapeutics
William G. Kaelin
GENOME MEDICINE (2009)
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Etienne Meylan et al.
NATURE (2009)
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
E. D. Michelakis et al.
BRITISH JOURNAL OF CANCER (2008)
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy
Sandra Turcotte et al.
CANCER CELL (2008)
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance
Norman Chan et al.
CANCER RESEARCH (2008)
Targeting cancer cells by synthetic lethality
Denise A. Chan et al.
CELL CYCLE (2008)
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
Bastiaan Evers et al.
CLINICAL CANCER RESEARCH (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: A high-value iterative loop
Ta-Chiang Liu et al.
MOLECULAR THERAPY (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
Archana Bommi-Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CDK inhibitors in cancer therapy: what is next?
Marcos Malumbres et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin
NATURE REVIEWS CANCER (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels
Nicholas Yagoda et al.
NATURE (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells
Aparna V. Sarthy et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A loss-of-function RNA interference screen for molecular targets in cancer
VN Ngo et al.
NATURE (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Lipase-catalyzed regioselective esterification of rapamycin: Synthesis of temsirolimus (CCI-779)
JX Gu et al.
ORGANIC LETTERS (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase
VM Loh et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes
E Petermann et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells
RS Bindra et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Y Wang et al.
CANCER CELL (2004)
A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells
TR Kau et al.
CANCER CELL (2003)
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
TR Brummelkamp et al.
NATURE (2003)
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells
S Dolma et al.
CANCER CELL (2003)
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors
DJ Skalitzky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Biallelic inactivation of BRCA2 in Fanconi anemia
NG Howlett et al.
SCIENCE (2002)
Perspectives on the development of a molecularly targeted agent
BJ Druker
CANCER CELL (2002)
Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions
M Kraakman-van der Zwet et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
A novel serine/threonine kinase gene, STK33, on human chromosome 11p15.3
AO Mujica et al.
GENE (2001)
Genetic synthetic lethality screen at the single gene level in cultured human cells
AH Simons et al.
NUCLEIC ACIDS RESEARCH (2001)
Use of isogenic human cancer cells for high-throughput screening and drug discovery
CJ Torrance et al.
NATURE BIOTECHNOLOGY (2001)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
MS Neshat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice
K Podsypanina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Cell biology - Principles for the buffering of genetic variation
JL Hartman et al.
SCIENCE (2001)
Establishment of a chemical synthetic lethality screen in cultured human cells
A Simons et al.
GENOME RESEARCH (2001)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
